Compare GFAI & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | HCWB |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 14.8M |
| IPO Year | 2020 | 2021 |
| Metric | GFAI | HCWB |
|---|---|---|
| Price | $0.36 | $3.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 159.6K | 61.4K |
| Earning Date | 04-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | $14.12 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | ★ N/A | $9.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.25 |
| 52 Week High | $1.38 | $7.35 |
| Indicator | GFAI | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 52.15 |
| Support Level | $0.31 | $0.37 |
| Resistance Level | $0.42 | $4.00 |
| Average True Range (ATR) | 0.03 | 0.44 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 61.90 | 50.53 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.